OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
CAMBRIDGE, Mass., April 06, 2016 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the upcoming 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 9:20 a.m. ET in New York, NY.
A live webcast of the presentation can be accessed by visiting the “Events and Presentations” tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.
About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.
For media: Liz Bryan Spectrum Science Communications, Inc. O: 202-955-6222 [email protected] For investors: Jonathan Poole Genocea Biosciences, Inc. O: 617-876-8191 [email protected]
